T. Rowe Price Associates’s Syndax Pharmaceuticals SNDX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $2.5M | Buy |
|
|||||
|
2025
Q4 | $1.99M | Buy |
|
|||||
|
2025
Q3 | $1.4M | Buy |
|
|||||
|
2025
Q2 | $706K | Buy |
|
|||||
|
2025
Q1 | $813K | Buy |
|
|||||
|
2024
Q4 | $754K | Buy |
|
|||||
|
2024
Q3 | $942K | Buy |
|
|||||
|
2024
Q2 | $990K | Buy |
|
|||||
|
2024
Q1 | $1.06M | Buy |
|
|||||
|
2023
Q4 | $568K | Buy |
|
|||||
|
2023
Q3 | $355K | Buy |
|
|||||
|
2023
Q2 | $481K | Buy |
|
|||||
|
2023
Q1 | $241K | Buy |
|
|||||
|
2022
Q4 | $238K | Buy |
|
|||||
|
2022
Q3 | $203K | Buy |
|
|||||
|
2021
Q4 | – | Sell |
|
|||||
|
2021
Q3 | $9.86M | Buy |
|
|||||
|
2021
Q2 | $7.22M | Sell |
|
|||||
|
2021
Q1 | $9.82M | Buy |
|
|||||
|
2020
Q4 | $3.81M | Buy |
|